Abstract: An optical interference device 100 is disclosed herein. In a described embodiment, the optical interference device 100 comprises a phase shifter array 108 for receiving a collimated beam of light. The phase shifter array 108 includes an array of cells 128 for producing optical light channels from respective rays of the collimated beam of light, with at least some of the optical light channels having varying phase shifts. The optical interference device 100 further includes a focusing lens 110 having a focal distance and arranged to simultaneously produce, from the optical light channels, a focused beam of light in its focal plane and an image downstream the phase shifter array 108 for detection by an optical detector 116.

Abstract: An optical interference device is disclosed herein. In a described embodiment, the optical interference device comprises a phase shifter array for receiving a collimated beam of light. The phase shifter array includes an array of cells for producing optical light channels from respective rays of the collimated beam of light, with at least some of the optical light channels having varying phase shifts. The optical interference device further includes a focusing lens having a focal distance and arranged to simultaneously produce, from the optical light channels, a focused beam of light in its focal plane and an image downstream the phase shifter array for detection by an optical detector. The optical interference device also includes an optical spatial filter arranged at the focal distance of the focusing lens and arranged to filter the focused beam of light to produce a spatially distributed interference light pattern in zeroth order for detection by the optical detector.

Abstract: An optical interference device 100 is disclosed herein. In a described embodiment, the optical interference device 100 comprises a phase shifter array 108 for receiving a collimated beam of light. The phase shifter array 108 includes an array of cells 128 for producing optical light channels from respective rays of the collimated beam of light, with at least some of the optical light channels having varying phase shifts. The optical interference device 100 further includes a focusing lens 110 having a focal distance and arranged to simultaneously produce, from the optical light channels, a focused beam of light in its focal plane and an image downstream the phase shifter array 108 for detection by an optical detector 116.

Abstract: Systematic comparisons of samples of adjacent clinically non malignant and tumor tissue from cancer of the gingivo buccal complex obtained during surgical resection of the tumor revealed significant differences in protein expression between the cancer tissue and the adjacent clinically non malignant tissue in each patient. This study has identified a set of new proteins which can differentiate between the epithelial tissue from cancer patients which may be useful for high-through put early detection, prognosis, and potential targets for therapy.

Abstract: The present invention relates to identification of a set of proteins, which elicit an autoantibody response in patients with cancer of gingivo-buccal complex. Systematic comparisons of serum samples from clinically normal individuals and from patients with cancer of gingivo-buccal complex has revealed significant differences in the presence of autoantibodies in sera against cellular antigens present in a cancer cell line. The autoantibody response to a single or combination of these protein antigens serves as a novel marker and can be utilized for screening, early detection, prognosis, and potential target for therapy. The invention also provides for the use of the identified protein antigens in immunoassays designed to detect the presence of serum antibodies to the specific protein antigens in sera from individuals that harbor such antibodies. The invention also relates to the use of the identified antigens as immunogens for stimulation of an immune response in patients expressing such protein antigens.

Abstract: The present invention relates to identification of a set of proteins, which elicit an autoantibody response in patients with cancer of gingivo-buccal complex. Systematic comparisons of serum samples from clinically normal individuals and from patients with cancer of gingivo-buccal complex has revealed significant differences in the presence of autoantibodies in sera against cellular antigens present in a cancer cell line. The autoantibody response to a single or combination of these protein antigens serves as a novel marker and can be utilized for screening, early detection, prognosis, and potential target for therapy. The invention also provides for the use of the identified protein antigens in immunoassays designed to detect the presence of serum antibodies to the specific protein antigens in sera from individuals that harbor such antibodies. The invention also relates to the use of the identified antigens as immunogens for stimulation of an immune response in patients expressing such protein antigens.

Abstract: Systematic comparisons of samples of adjacent clinically non malignant and tumor tissue from cancer of the gingivo buccal complex obtained during surgical resection of the tumor revealed significant differences in protein expression between the cancer tissue and the adjacent clinically non malignant tissue in each patient. This study has identified a set of new proteins which can differentiate between the epithelial tissue from cancer patients which may be useful for high-through put early detection, prognosis, and potential targets for therapy.